IMV Inc IMVIQ

Re: Abstract Presentation on Feb 06

[QM45]

• Abstract

 

121 Patients... See below: 

Authors:

Oliver Dorigo, Stephan Fiset, Lisa Diana MacDonald, Yogesh Bramhecha, Olga Hrytsenko, Brennan Dirk, Gabriela Nicola Rosu, Marianne Stanford; Stanford Cancer Institute, Stanford, CA; IMV Inc., Quebec, QC, Canada; IMV Inc., Dartmouth, NS, Canada

Abstract Disclosures

Research Funding:

IMV Inc., Pharmaceutical/Biotech Company.

Background:Survivin has emerged as an attractive target for T cell-based immunotherapy because of its essential role in tumor biology and its tumor-specific expression in multiple tumor types. DPX-Survivac is a novel T cell immunotherapy that uses the DPX platform to elicit strong and sustained survivin-specific T cell responses against tumor cells. DPX is designed to extend the duration and robustness of targeted immune responses by requiring active uptake of antigens by antigen presenting cells at the injection site. DPX-Survivac incorporating survivin targets within the DPX platform is therefore a relevant approach for treatment of survivin-expressing cancers to generate strong T cell responses that infiltrate tumors and result in measurable anti-tumor responses.Methods:121 patients with platinum sensitive or resistant, advanced ovarian, fallopian tube or peritoneal cancer were treated with DPX-Survivac with or without drug combinations. Data from 3 different clinical trials were analyzed for systemic immune responses, tumor immune infiltrates and clinical tumor responses. Patients were enrolled in both the maintenance (N = 56) and recurrent (N = 65) disease settings.Results:DPX-Survivac generated survivin-specific T cells in 80% of patients as demonstrated by IFN-γ ELISPOT of PBMCs. Paired pre- and post-treatment tumor samples were collected from 37 patients. Survivin-specific T cells were found in the tumor microenvironment post-treatment using TCR-β sequencing. Clinical anti-tumor responses were correlated with increased infiltration of T cells into tumors following treatment with DPX-Survivac. An increase in T cell signaling in post-treatment tumor tissue was shown by RNAseq along with upregulation of cytotoxic markers, NK and B cell markers. Importantly, the antigen-specific T cells retain their functionality throughout the duration of treatment.Conclusions:DPX-Survivac stimulates significant clinical anti-tumor responses by inducing strong and sustained survivin-specific T cell responses and increasing infiltration of target-specific T cells into tumors. Clinical trial information: NCT01416038; NCT03332576; NCT02785250